LS

Lite Strategy, Inc.

LITS·NASDAQ

$1.43

-3.5%
HealthcareBiotechnology

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$52.60M
EPS-2.3900
P/E Ratio-1.89
Earnings Date02/11/2026

lits

Additional Paid-In Capital

Last Annual Value

421.10M

3-Year CAGR

%

5-Year CAGR

3%

10-Year CAGR

1%

LS

Lite Strategy, Inc. Competitors Analysis of Additional Paid-In Capital

LITS · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
421.10M
-0.7%2.7%N/A 
784.71M
6.7%8.9%24.6%
627.98M
16.4%19.9%N/A
387.25M
17.7%225.9%N/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
290.53M
4.3%10.6%N/A
751.68M
2.7%8.2%N/A
0.00
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
548.13M
5.4%6.1%13.1%
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
773.79M
12.0%10.4%N/A
551.08M
1.0%3.0%N/A
500.21M
3.2%4.3%N/A
LS

Lite Strategy, Inc. Fair Value Envelope

LITS · NASDAQ

Our analysis suggests that LITS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.43, this represents a potential HIDDEN relative to our calculated worth for Lite Strategy, Inc..

Intrinsic Value
Current Price: $1.43